Recombinant Human IGF-I/IGF-1 Receptor Grade Protein

SDS-Page: Recombinant Human IGF-I/IGF-1 Receptor Grade Protein [NBP2-34946] - SDS-PAGE with Recombinant human IGF-I/IGF-1 Receptor Grade Protein.

Product Discontinued

Recombinant Human IGF-I/IGF-1 Receptor Grade Protein Summary

• Description: A single, non-glycosylated polypeptide chain corresponding to 83 residues of IGF-I/IGF-1.
  
  

  Source: Escherichia coli

  Amino Acid Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA

• Details of Functionality: Assay 1: Fully biologically active when compared to standard. Measured in a serum-free cell proliferation assay using human MCF-7 cells. The ED50 for this effect is 0.3-1.5 ng/ml, corresponding to a specific activity of > 6.7 x 10^5 IU/mg. Assay 2: Fully biologically active when compared to standard. The ED50 as determined by the stimulation of protein synthesis using rat L6 myoblasts is less than 10 ng/ml, corresponding to a specific activity of > 1.0 x 10^5 IU/mg.
• Source: E. coli
• Protein/Peptide Type: Biologically Active Protein
• Gene: IGF1
• Purity: >98%, by SDS-PAGE
• Endotoxin Note: Less than 50 EU/mg of rHuLR3 IGF-1 as determined by LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Functional
  • SDS-Page
• Theoretical MW: 9.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.
• Buffer: Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0.
• Concentration: LYOPH
• Purity: >98%, by SDS-PAGE
• Reconstitution Instructions: Recommended to centrifuge prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/mL. Apportion stock solutions into working aliquots and store at <-20C.

Alternate Names for Recombinant Human IGF-I/IGF-1 Receptor Grade Protein

• IBP1
• IGF1
• IGF-1
• IGF1A
• IGFI
• IGF-I
• IGF-IA
• IGF-IB
• insulin-like growth factor 1 (somatomedin C)
• insulin-like growth factor 1
• insulin-like growth factor I
• insulin-like growth factor IA
• insulin-like growth factor IB
• Mechano growth factor
• MGF
• Somatomedin A
• Somatomedin C
• somatomedin-C

Background

Insulin-like Growth Factor I (IGF-I), also known as Somatomedin C, is the dominant effector of Growth Hormone (GH). IGF-I regulates glucose, fatty acid, and protein metabolism, steroid hormone activity, cartilage and bone metabolism, muscle regeneration, tumor progression, and cellular differentiation and migration. IGF-I effects are mediated primarily by IGF-I R, and its bioavailability is regulated by IGF binding proteins (IGFBPs). Mature human IGF-I shares about 95% aa sequence identity with the mouse and rat IGF-I. Long R3 IGF-I (LR3 IGF-I) is a synthetic analog of IGF-I that has a Glu3Arg substitution and a 13 aa N-terminal extension derived from methionyl porcine GH. It retains the ability to bind IGF-I R and Insulin R but shows reduced affinity for IGFBPs. As a result, LR3 IGF-I has an increased half-life and displays increased biological potency compared to IGF-I.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 2 years from date of receipt.

Bioinformatics

• Gene Symbol: IGF1